Analysts See 100% Upside To Rigel After Tavalisse Approval By: Benzinga via Benzinga April 18, 2018 at 13:23 PM EDT Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced Tuesday the approval of its Tavalisse for chronic immune thrombocytopenia — ... Read More >> Related Stocks: Amgen Rigel Pharmaceuticals